Volume 27, Number 12—December 2021
CME ACTIVITY - Synopsis
Clinical Characteristics of Corynebacterium Bacteremia Caused by Different Species, Japan, 2014–2020
Ryosuke Yamamuro
, Naoto Hosokawa, Yoshihito Otsuka, and Ryosuke Osawa
, Naoto Hosokawa, Yoshihito Otsuka, and Ryosuke Osawa
Table 3
Antimicrobial susceptibility testing of Corynebacterium species isolated from blood culture, Japan, 2014–2020*
| Species | Susceptible/tested (%) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PEN | CRO | MEM | GEN | CIP | MIN | CLI | ERY | VAN | LZD† | |
| C. striatum, n = 67 |
14/67 (21) |
5/67 (7) |
17/67 (25) |
59/67 (88) |
3/67 (4) |
67/67 (100) |
8/67 (12) |
13/67 (19) |
67/67 (100) |
4/4 (100) |
| C. jeikeium, n = 14 |
0/14 (0) |
0/14 (0) |
5/14 (36) |
5/14 (36) |
0/14 (0) |
14/14 (100) |
0/14 (0) |
0/14 (0) |
14/14 (100) |
3/3 (100) |
| Other species, n = 34 |
27/34 (79) |
22/34 (65) |
31/34 (91) |
30/34 (88) |
10/34 (29) |
34/34 (100) |
6/34 (18) |
16/34 (47) |
34/34 (100) |
2/2 (100) |
| All, n = 115 | 41/115 (36) | 27/115 (23) | 53/115 (46) | 94/115 (82) | 13/115 (11) | 115/115 (100) | 14/115 (12) | 29/115 (25) | 115/115 (100) | 9/9 (100) |
*CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; GEN, gentamicin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; VAN, vancomycin.
†Antimicrobial susceptibility testing for linezolid was only performed if requested by physicians.
Page created: October 06, 2021
Page updated: November 17, 2021
Page reviewed: November 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.